FDA Approves Botox for Treatment of Forehead Lines

October 30, 2017

Global pharmaceutical company Allergan has announced the FDA approval of Botox for its third indication, the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis, or muscle thinning activity in adults. This recent approval makes Botox the first and only neurotoxin specifically geared toward the improvement of three facial treatment areas: crow’s feet, forehead lines, and glabellar lines. “Allergan recognizes that forehead lines are a top area of concern for patients,” says David Nicholson, chief research and development officer at Allergan.
Read more at American Spa >> 

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Just Digital Launches Aesthera Marketing, a Dedicated Agency for Med Spas and Aesthetic Practices
    • AI Visibility Report Details How Patients Can Find Your Brand
    • RealSelf Q1 2026 Trend Report Reveals Surge in Regenerative Aesthetics, Skin Rejuvenation
    • Biohacking Beauty: How to Elevate Aesthetic Medicine with Peptides
    • Pacific Reliance Medical M&A Advisors to Broker Sale of 21 Face to Face Medical Spa Locations